Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CACNA1G-AS1 modulators(CACNA1G antisense RNA 1 modulators), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 22 May 2023 |